Loews Corporation (NYSE: L), a diversified company with businesses in the insurance, energy, hospitality, and packaging industries, on Monday reported higher revenue and profit for the third quarter of 2024.
- Net income attributable to Loews increased to $401 million in Q3 from $253 million in the year-ago quarter
- Core income for the CNA subsidiary, on an adjusted basis, edged up to $293 million in the September quarter from $289 million in Q3 2023
- At $4.47 billion, third-quarter revenues were up 14% from the prior-year period
- On a per-share basis, Q3 earnings moved up to $1.82 per share from $1.12 per share in the third quarter of 2023
- Excluding the prior-year third quarter’s $37 million charge for the termination of Loews’s defined benefit pension plan, net income grew 38% year-over-year
- The company repurchased 0.8 million shares of its common stock during the quarter for a total cost of $64 million
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
